摘要
目的观察噻托溴铵吸入剂治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效。方法选择2016年7月至2018年7月中铁一局集团咸阳中心医院收治的COPD患者100例作为研究对象,采用随机数表法将患者分为对照组和观察组,每组50例,所有患者均给予氧疗、预防呼吸道感染等治疗,在此基础上对照组给予布地奈德治疗,观察组采用噻托溴铵吸入剂治疗,均治疗4周。比较两组患者治疗后的临床效果,以及治疗前后的免疫球蛋白白细胞介素-8(IL-8)、肿瘤坏死因子α(TNF-α)、中性粒细胞髓过氧化物酶(MPO)、第1秒用力呼气容积(FEV1)、FEV1/FVC、最大呼气流量(PEF)水平和不良反应发生情况。结果观察组患者的治疗总有效率为94.00%,明显高于对照组的70.00%,差异有统计学意义(P<0.05);治疗前,两组患者的IL-8、TNF-α、MPO比较差异均无统计学意义(P>0.05);治疗后,观察组患者的IL-8、TNF-α、MPO分别为(0.41±0.17)pg/mL、(58.51±8.26)pg/mL、(13.09±3.21)pg/mL,明显低于对照组的(0.62±0.23)pg/mL、(75.43±11.62)pg/mL、(19.87±4.35)pg/mL,差异均具有统计学意义(P<0.05);治疗前,两组患者的FEV1、FEV1/FVC、PEF比较差异均无统计学意义(P>0.05);治疗后,观察组患者的FEV1、FEV1/FVC、PEF分别为(1.92±0.58)L、(65.84±6.12)%、(3.98±0.42)L/s,明显高于对照组的(1.61±0.56)L、(56.18±5.29)%、(3.05±0.44)L/s,差异均有统计学意义(P<0.05);观察组患者的不良反应发生总发生率为4.00%,明显低于对照组18.00%,差异有统计学意义(P<0.05)。结论噻托溴铵吸入剂治疗稳定期慢性阻塞性肺疾病患者可有效改善患者炎症因子及肺功能水平,临床治疗效果显著。
Objective To study the curative efficacy of tiotropium bromide inhalation in treatment of stable COPD.Methods A total of 100 patients with chronic obstructive pulmonary disease,who admitted to Department of Internal Medicine,Xianyang Central Hospital of China Railway First Group from July 2016 to July 2018,were selected and divided into the observation group and control group according to random number table method,with 50 patients each group.All the patients were given basic treatment such as oxygen therapy,quitting smoking and preventing respiratory tract infection.The control group received additionally budesonide treatment,and the observation group received additionally tiotropium bromide inhalation treatment,the treatment course was 4 weeks.The clinical effects after treatment were compared,including immunoglobulin interleukin-8(IL-8),tumor necrosis factor alpha(TNF-α),neutrophil myelperoxidase(MPO),forced expiratory volume at the first second(FEV1),FEV1/FVC,maximum expiratory flow(PEF)and adverse reactions.Results After treatment,the total effective rate of the observation group was 94.00%,which was significantly higher than 70.00%in the control group(P<0.05).Before treatment,there was no statistically significant difference in IL-8,TNF-αand MPO between the two groups(all P>0.05).After treatment,the levels of IL-8,TNF-α,MPO in the observation group were(0.41±0.17)pg/m L,(58.51±8.26)pg/m L,(13.09±3.21)pg/m L,respectively,which were significantly lower than corresponding(0.62±0.23)pg/m L,(75.43±11.62)pg/m L,(19.87±4.35)pg/m L in the control group(all P<0.05).After treatment,the levels of FEV1,FEV1/FVC,PEF in the observation group were(1.92±0.58)L,(65.84±6.12)%,(3.98±0.42)L/s,respectively,which were significantly higher than corresponding(1.61±0.56)L,(56.18±5.29)%,(3.05±0.44)L/s in the control group(all P<0.05).The total incidence of adverse reactions in the observation group was 4.00%,which was significantly lower than 18.00%in the control group(P<0.05).Conclusion Tiotropium bromide inhalation has a significant effect in the treatment of patients with stable COPD,which can effectively improve the level of inflammatory cytokines and lung function in the patients.
作者
贾美莹
王银叶
JIA Mei-ying;WANG Yin-ye(Department of Internal Medicine,Xianyang Central Hospital of China Railway First Group,Xianyang 712000,Shaanxi,CHINA)
出处
《海南医学》
CAS
2020年第5期589-592,共4页
Hainan Medical Journal
基金
陕西省咸阳市卫计委医学科研课题(编号：201601092)
关键词
噻托溴铵吸入剂
稳定期
慢性阻塞性肺疾病
炎症因子
肺功能
疗效
Tiotropium bromide inhalation
Stable period
Chronic obstructive pulmonary disease(COPD)
Inflammatory cytokines
Lung function
Therapeutic effect
作者简介
通讯作者:贾美莹,E-mail:13369109629@139.com。
